Takeda and partner Zinfandel cancelled testing of Actos as a potential Alzheimer’s therapy; Shanghai Pharma will open an R&D site in San Diego later this year; WuXi NextCODE looks to significantly grow its B2C business in China; plus more need-to-know news from Asia's pharma industry.Original Article
FiercePharmaAsia—Takeda’s Alzheimer’s flop, Shanghai Pharma’s U.S. plan, NextCODE talk
